The biggest leading signal this week isn't on cable news — it's in Wikipedia traffic. Ketamine therapy pageviews jumped 29% week-over-week, pushing it to the top of the Emerging Demand Index at 1.83, while HRT followed close behind at 1.62 on a 25% WoW pageview lift. Operators in mental health and menopause should treat this as a two-to-four-week early warning before consult requests move.

Emerging Demand — What to Watch

  • Ketamine therapy (EDI 1.83) — Wikipedia pageviews +29% WoW with no corresponding FDA action, indicating consumer-driven research, not regulatory news. Specialties: Mental Health.
  • HRT (EDI 1.62) — Wikipedia pageviews +25% WoW, continuing a multi-quarter trend of menopause demand expansion. No FDA catalyst — this is sustained patient-led interest. Specialties: Menopause, Women's Health.
  • "Olivia Wilde Ozempic" (EDI 1.13) — Google rising query flagged Breakout (>5000% lift), a classic celebrity-attribution spike. Mechanism is media coverage, not clinical demand — discount accordingly.
  • "Kris Jenner Ozempic experience" (EDI 1.13) — Another Breakout celebrity query. Three of the top eight EDI entries are celebrity-Ozempic variants, signaling a fresh tabloid cycle around GLP-1s.
  • Ozempic itself (EDI 0.61) — Mixed signal: rising celebrity queries pull the score up, but Wikipedia pageviews are down 14% WoW, suggesting the curiosity wave has shifted from "what is it" to "who is on it." Net: brand awareness is saturating.

Search Intent

Google Trends shows no nationally rising conditions this week — a notably quiet coincident picture that contradicts the EDI's ketamine and HRT signals, which is exactly what you'd expect from leading indicators that haven't yet translated to search volume. On the falling side, rotator cuff queries dropped 15% (4-week avg 62 vs prior 73) and joint replacement fell 12% (45 vs 51), both consistent with a mid-June ortho-elective slowdown as patients defer for summer travel.

Structural Markets

No new BRFSS state-level deltas surfaced this week worth flagging against national prevalence baselines. Operators should continue using prior weeks' obesity and diabetes prevalence gaps as the planning anchor; nothing in this week's data shifts the structural picture.

The Bottom Line

Shift a slice of June ad spend from orthopedic electives (where intent is fading 12–15%) toward ketamine therapy and HRT landing pages — the Wikipedia-led signals typically lead consult bookings by two to four weeks. Treat the celebrity-Ozempic Breakout queries as brand-awareness noise, not new patient demand; the underlying Ozempic pageview decline says the category is maturing, not accelerating.